The impact of body mass index (BMI) on the progression-free survival of CDK4/6 inhibitors in metastatic breast cancer patients (MBC)

Artac, M.Caglayan, D.Kocak, M. Z.Geredeli, C.Tatli, A. M.Goksu, S. SezginImaz, M. Karakurt Ery2024-02-232024-02-2320220923-75341569-8041https://doi.org/10.1016/j.annonc.2022.07.274https://hdl.handle.net/20.500.12452/11582Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) -- SEP 09-13, 2022 -- ELECTR NETWORK[Abstract Not Availabe]eninfo:eu-repo/semantics/openAccess[Keyword Not Available]The impact of body mass index (BMI) on the progression-free survival of CDK4/6 inhibitors in metastatic breast cancer patients (MBC)Conference Object337S644S645Q1WOS:000866211600229Q110.1016/j.annonc.2022.07.274